Clinical trials: Capsule Opacification
Cataract
Visual Outcomes After Cataract Surgery: Multifocal AcrySof® IQ ReSTOR® Intraocular Lenses Versus Monofocal Intraocular Lenses
The purpose of this study is to assess and compare visual outcomes of the AcrySof® IQ ReSTOR® +3.0 D intraocular lens (IOL) to a commercially available monofocal IOL in cataract patients.
- Trial name
- NCT01290068
- Testing
- AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL, AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL, Monofocal IOL
- Volunteers
- 208 people
- Sponsor
- Alcon Research
Cataract
Optimizing the Assessment of Refractive Outcomes After Cataract Surgery
The purpose of this study is to evaluate current available assessments (automated vs. manual) with which manifest refraction data and biometric variables are obtained to understand if data from an automated refractor can be…
- Trial name
- NCT02842151
- Testing
- Manifest refraction, ACRYSOF® IQ Monofocal IOL Model SN60WF, Topcon® KR-1W Wave-Front Analyzer
- Volunteers
- 162 people
- Sponsor
- Alcon Research
Post-Surgical Ocular Pain, Post-Surgical Ocular Inflammation
OTX-14-003: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Ocular Inflammation and Pain After Cataract Surgery
The objective of the study was to evaluate the safety and efficacy of OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use when placed in the canaliculus of the eyelid for the treatment of post-surgical inflammation and…
- Trial name
- NCT02089113
- Testing
- Dexamethasone
- Volunteers
- 241 people
- Sponsor
- Ocular Therapeutix, Inc.
Ocular Inflammation and Pain
Phase II Study Evaluating Safety/Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery
To evaluate the safety and efficacy of OTX-DP as a sustained release drug (dexamethasone) depot when placed in the canaliculus of the eyelid for the treatment of ocular inflammation and pain in subjects who have undergone…
- Trial name
- NCT01666210
- Testing
- OTX-DP (Dexamethasone punctum plug)
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Ocular Therapeutix, Inc.
Ocular Inflammation and Pain After Cataract Surgery
Efficacy and Safety of APP13007 for Treatment of Inflammation and Pain After Cataract Surgery Including a Corneal Endothelial Cell Sub-study
This Phase 3 study will evaluate APP13007 in comparison to the matching vehicle placebo in a randomized, parallel-group, double-masked fashion.
- Trial name
- NCT04810962
- Testing
- APP13007, 0.05%
- Where
- 31 sites in United States
- Volunteers
- 370 people
- Sponsor
- Formosa Pharmaceuticals, Inc.
Posterior Capsule Opacification
Influence of CleaRing Open-capsule Device on Refractive Predictability in Cataract Patients (Part 2)
The Hanita CleaRing device is an intraocular implant designed for inhibition of PCO leading to reduction in the Nd:YAG treatment rate.
- Trial name
- CleaRing (NCT06083025)
- Testing
- CleaRing
- Where
- Israel
- Volunteers
- 25 people
- Sponsor
- Hanita Lenses
Cataract
A Study Assessing Safety and Efficacy of MD-15 Intraocular Lens in Patients With Aphakic Eye After Cataract Surgery
To evaluate safety and efficacy of MD-15 intraocular lens implanted into the aphakic eyes
- Trial name
- NCT02888210
- Testing
- MD-15 Intraocular Lens
- Where
- Japan
- Volunteers
- 110 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Pain, Inflammation
Safety/Efficacy of Nepafenac Punctal Plug Delivery System Compared to Placebo to Control Ocular Pain/Inflammation After Cataract
This is a Phase 2, multi-center, randomized, parallel-arm, double-masked, placebo-controlled study. One (1) to 2 days prior to their scheduled cataract surgery, each study subject will be randomized (2:1) in to one of two…
- Trial name
- NCT03496467
- Testing
- Nepafenac PPDS
- Where
- 3 sites in United States
- Volunteers
- 56 people
- Sponsor
- Mati Therapeutics Inc.
Ocular Inflammation and Pain After Cataract Surgery
A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of APP13007 to Treat Inflammation and Pain After Cataract Surgery
This is a Phase 2a, 2-part study (designated Parts A and B) that will evaluate APP13007 dose strength and dosing frequency in a randomized double-masked fashion for comparison to the respective matching vehicle placebo.
- Trial name
- NCT04089735
- Testing
- APP13007, 0.05%, APP13007, 0.1%
- Where
- 9 sites in United States
- Volunteers
- 165 people
- Sponsor
- Formosa Pharmaceuticals, Inc.
Cataract, Presbyopia
Comparative Analysis of the Visual Performance and Patient Satisfaction After Cataract Surgery With Implantation of a Medicontur Monofocal (877PAY) or a Medicontur Extended Depth of Focus (877PEY) IOL
The purpose of this multi-center, prospective, randomized, comparative clinical investigation was to evaluate and compare the visual performance at far, intermediate and near distances, the presence of photopic phenomena and…
- Conditions
- Cataract, Presbyopia, Ametropia
- Trial name
- NCT06642779
- Testing
- VFQ- 25 (Visual Function Questionnaire), Optical Biometry, Slit lamps / Fundoscopy / Biomicroscopy
- Where
- 3 sites in Hungary
- Volunteers
- 64 people
- Sponsor
- Medicontur Medical Engineering Ltd
Cataract, Presbyopia
IC-8 Apthera IOL New Enrollment Post Approval Study
The purpose of this study is to verify the post-market safety of the IC-8 Apthera IOL after the treatment of posterior capsular opacification (PCO), an expected complication related to IC-8 Apthera IOL implantation.
- Conditions
- Cataract, Presbyopia, Posterior Capsule Opacification
- Trial name
- NCT06060041
- Where
- 14 sites in United States
- Volunteers
- 435 people
- Sponsor
- Bausch & Lomb Incorporated
Ocular Inflammation and Pain
Efficacy and Safety of APP13007 for Treatment of Inflammation and Pain After Cataract Surgery
This Phase 3 study will evaluate APP13007 in comparison to the matching vehicle placebo in a randomized, parallel-group, double-masked fashion.
- Trial name
- NCT04739709
- Testing
- APP13007, 0.05%
- Where
- 35 sites in United States, Puerto Rico
- Volunteers
- 378 people
- Sponsor
- Formosa Pharmaceuticals, Inc.
Lens Implantation, Intraocular
Evaluation of Safety and Performance Outcomes of Eyedeal IOL Implantation After Cataract Removal
A cataract is the clouding of the natural lens in the eye and is very common as when getting older. A cloudy lens makes it difficult to see.
- Trial name
- NCT05776095
- Testing
- Cataract surgery, Eyedeal® Model PX65AS1 IOL
- Where
- 2 sites in Germany, Lithuania
- Volunteers
- 97 people
- Sponsor
- Xi'an Eyedeal Medical Technology Co., Ltd
Cataract
Influence of DisCoVisc Ophthalmic Viscosurgical Device (OVD) on Intraoperative Aberrometry Readings
The purpose of the study is to develop a nomogram that correlates intraoperative, aphakic refraction measurements when the anterior chamber is pressurized with either balanced salt solution (BSS) or DisCoVisc; and to understand…
- Trial name
- NCT03751033
- Testing
- BSS, DiscoVisc
- Where
- 3 sites in United States
- Volunteers
- 120 people
- Sponsor
- Clinical Research Consultants, Inc.
Ocular Discomfort
A 8 Weeks Study to Evaluate Efficacy & Safety of rhNGF vs Vehicle in Patients After Cataract and Refractive Surgery
The primary objective of this exploratory study is to assess preliminary efficacy and safety of rhNGF when administered as eye drops to patients after cataract and refractive surgery.
- Trial name
- NCT03035864
- Testing
- rhNGF, Vehicle
- Where
- Italy
- Volunteers
- 180 people
- Sponsor
- Dompé Farmaceutici S.p.A
Corneal Edema After Cataract Surgery
A Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Cataract Surgery
The purpose of this study is to assess the safety and efficacy of K-321 in subjects after cataract surgery
- Trial name
- NCT05528172
- Testing
- Ripasudil
- Where
- 45 sites in United States, Puerto Rico
- Volunteers
- 330 people
- Sponsor
- Kowa Research Institute, Inc.
Endophthalmitis
Safety and Efficacy of Intracameral Zimoxin for Prevention of Endophthalmitis After Cataract Surgery
Intracameral injection of 0.1% moxifloxacin solution after cataract surgery to prevent endophthalmitis
- Trial name
- NCT03244072
- Testing
- Moxifloxacin
- Where
- United States
- Volunteers
- 60,000 people, healthy volunteers welcome
- Sponsor
- Jason Ahee, M.D.
Cataract
Nepafenac Opthalmic Suspension 0.1% Compared to Acular LS for Treatment of Inflammation After Cataract Surgery
The purpose of this study is to compare the effectiveness of Nepafenac Ophthalmic Suspension, 0.1% eye drops to Acular LS eye drops, used before and after cataract surgery, for treating inflammation in the eye.
- Trial name
- NCT00333255
- Testing
- Nepafenac Ophthalmic Suspension, 0.1%
- Where
- United States
- Volunteers
- 267 people
- Sponsor
- Alcon Research
Cataract
A Safety and Efficacy Study of a Dexamethasone Drug Delivery System for Postoperative Inflammation and Pain After Cataract Surgery
This is a safety and efficacy study of a Dexamethasone Drug Delivery System for anterior segment inflammation and pain following cataract extraction with lens implantation.
- Trial name
- NCT01605942
- Testing
- Dexamethasone Drug Delivery System
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Allergan
Cataract
Posterior Capsule Opacification (PCO) Evaluation of the AcrySof SN60AT Lens vs. SN60WF Lens
To assess posterior capsule opacification (PCO) in patients implanted with either the AcrySof SN60AT lens or the AcrySof SN60WF lens.
- Trial name
- NCT00762021
- Testing
- SN60AT, SN60WF
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- Alcon Research